EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study

Reiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, Tohru Yorifuji, David Ng, Ron G Rosenfeld, Yuko Hoshino, Akifumi Okayama, Nozomi Ebata, Masayoshi Hosoi, Shinichi Nakamuta, Roy Gomez und 2 weitere

Endocrine Journal · 2026 · 73 (1) · 21-32

DOI: 10.1507/endocrj.ej24-0625 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Endocrine Journal, 2026. Verfasst von Reiko Horikawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Growth Disorders, Dwarfism, Pituitary. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: OPKO Health, Pfizer Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneGrowth DisordersDwarfism, PituitaryHumansMaleChildFemaleJapanBody HeightChild, PreschoolTreatment OutcomeDrug Administration ScheduleAdolescentEast Asian People

Stichwörter der Autor:innen

Growth hormone deficiencyJapanLong-acting growth hormoneSomatrogonSomatropin

Substanzen

Human Growth Hormonesomatrogon

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan.
  • Tanaka Growth Clinic, Tokyo, Japan.
  • Department of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • 2nd Department of Internal Medicine, Date Red Cross Hospital, Hokkaido, Japan.
  • WuXi Clinical, Austin, TX, USA.
  • Oregon Health & Science University, Portland, OR, USA.

Förderung

  • OPKO Health
  • Pfizer Japan

Zitieren

APA

Horikawa, R., Tanaka, T., Hasegawa, Y., Yorifuji, T., Ng, D., Rosenfeld, R. G., Hoshino, Y., Okayama, A., Ebata, N., Hosoi, M., Nakamuta, S., Gomez, R., Pastrak, A., & Castellanos, O. (2026). Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. Endocrine Journal, 73(1), 21-32. https://doi.org/10.1507/endocrj.ej24-0625

Vancouver

Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, et al. Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study. Endocrine Journal. 2026;73(1):21-32. doi:10.1507/endocrj.ej24-0625

BibTeX
@article{Horikawa2026,
  author = {Horikawa, Reiko and Tanaka, Toshiaki and Hasegawa, Yukihiro and Yorifuji, Tohru and Ng, David and Rosenfeld, Ron G and Hoshino, Yuko and Okayama, Akifumi and Ebata, Nozomi and Hosoi, Masayoshi and Nakamuta, Shinichi and Gomez, Roy and Pastrak, Aleksandra and Castellanos, Orlando},
  title = {Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study},
  journal = {Endocrine Journal},
  year = {2026},
  volume = {73},
  number = {1},
  pages = {21--32},
  doi = {10.1507/endocrj.ej24-0625}
}
Kostenlos starten →